+

WO2005007129A3 - Topical formulations with bioactive components - Google Patents

Topical formulations with bioactive components Download PDF

Info

Publication number
WO2005007129A3
WO2005007129A3 PCT/CA2004/001049 CA2004001049W WO2005007129A3 WO 2005007129 A3 WO2005007129 A3 WO 2005007129A3 CA 2004001049 W CA2004001049 W CA 2004001049W WO 2005007129 A3 WO2005007129 A3 WO 2005007129A3
Authority
WO
WIPO (PCT)
Prior art keywords
topical formulations
bioactive components
drug
formulation
maximum solubility
Prior art date
Application number
PCT/CA2004/001049
Other languages
French (fr)
Other versions
WO2005007129A2 (en
Inventor
Richard T Liggins
Original Assignee
Angiotech Int Ag
Richard T Liggins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiotech Int Ag, Richard T Liggins filed Critical Angiotech Int Ag
Publication of WO2005007129A2 publication Critical patent/WO2005007129A2/en
Publication of WO2005007129A3 publication Critical patent/WO2005007129A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A topical formulation for drug delivery, the formulation comprising an organic solvent and a drug, the drug having a maximum solubility in the formulation, where the drug is present in the formulation at a concentration of at least 50% of the drug's maximum solubility.
PCT/CA2004/001049 2003-07-17 2004-07-19 Topical formulations with bioactive components WO2005007129A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48870303P 2003-07-17 2003-07-17
US60/488,703 2003-07-17

Publications (2)

Publication Number Publication Date
WO2005007129A2 WO2005007129A2 (en) 2005-01-27
WO2005007129A3 true WO2005007129A3 (en) 2005-08-04

Family

ID=34079449

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2004/001049 WO2005007129A2 (en) 2003-07-17 2004-07-19 Topical formulations with bioactive components

Country Status (1)

Country Link
WO (1) WO2005007129A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872050B2 (en) 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US8501818B2 (en) 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
HU227970B1 (en) 2007-07-10 2012-07-30 Egis Gyogyszergyar Nyrt Pharmaceutical compositions containing silicones of high volatility
EP2273876B1 (en) 2008-03-27 2019-03-06 Helsinn Healthcare SA Stabilized compositions of alkylating agents and methods of using same
JP5941751B2 (en) * 2012-05-21 2016-06-29 ライオン株式会社 Oil-in-water emulsion composition
US11154535B2 (en) 2012-07-31 2021-10-26 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US10045935B2 (en) 2012-07-31 2018-08-14 Egis Pharmaceuticals Plc Transdermal formulation containing COX inhibitors
US9592188B2 (en) 2014-05-22 2017-03-14 Yansong Liu Method of treating or reducing the severity of dermatological conditions
AU2016255725B2 (en) 2015-04-27 2021-09-23 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center EGR1 targeting molecules for the treatment of inflammatory and hyperproliferative conditions
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
GB2603645B (en) * 2019-07-22 2023-03-01 Uniao Brasileira De Educacao Catolica Polypeptides having anti-senescent effects and uses thereof
WO2022074649A1 (en) * 2020-10-05 2022-04-14 Ichilov Tech Ltd. Treatment of skin diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627187A (en) * 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
WO1998024427A2 (en) * 1996-12-02 1998-06-11 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO2000040238A1 (en) * 1999-01-08 2000-07-13 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
WO2001036007A2 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627187A (en) * 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
WO1998024427A2 (en) * 1996-12-02 1998-06-11 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating or preventing inflammatory diseases
WO2000040238A1 (en) * 1999-01-08 2000-07-13 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
WO2001036007A2 (en) * 1999-11-12 2001-05-25 Angiotech Pharmaceuticals, Inc. Compositions of a combination of radioactive therapy and cell-cycle inhibitors
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SASAKI H ET AL: "ENHANCING EFFECT OF PYRROLIDONE DERIVATIVES ON TRANSDERMAL PENETRATION OF 5-FLUOROURACIL, TRIAMCINOLONE ACETONIDE, INDOMETHACIN, AND FLURBIPROFEN", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 80, no. 6, June 1991 (1991-06-01), pages 533 - 538, XP009020814, ISSN: 0022-3549 *

Also Published As

Publication number Publication date
WO2005007129A2 (en) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2006037116A3 (en) Semi-solid delivery vehicle and pharmaceutical compositions
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
WO2005004895A3 (en) Compositions and methods for enhanced mucosal delivery of growth hormone
WO2000040203A3 (en) Polymeric delivery agents and delivery agent compounds
CA2259297A1 (en) Parenteral paclitaxel in a stable non-toxic formulation
HK1099707A1 (en) Insulin compositions with improved absorption
WO2006082588A3 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2005007129A3 (en) Topical formulations with bioactive components
PL376154A1 (en) Triazaspiro[5.5]undecane derivatives and drugs comprising the same as the active ingredient
CA2567575A1 (en) Organo-gel formulations for therapeutic applications
WO2005048952A3 (en) Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle
WO2005018574A3 (en) Immunostimulatory combinations and treatments
WO2002092147A3 (en) Optimization of the molecular properties and formulation of proteins delivered by inhalation
HUP0500846A3 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
ATE275393T1 (en) SOLID DISPERSIONS WITH NITRATACTIVE ACTIVE INGREDIENTS
WO2007133751A3 (en) Base-stabilized polyorthoester formulations
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
CA2352915A1 (en) Pharmaceutical compositions containing mupirocin
WO2003066597A3 (en) Guanidino compounds
EP1637132A4 (en) External preparation for athlete´s foot treatment
RS106704A (en) Stabilised pharmaceutical compositions on the basis of polyoxyethylated castor oil and method for manufacturing the same
WO2003057176A3 (en) Porphyrins with virucidal activity
WO2005034861A3 (en) A dried biotherapeutic composition, uses, and device and methods for administration thereof
WO2001085139A3 (en) Semi-solid delivery vehicle and pharmaceutical compositions
WO2003092655A3 (en) Use of active ingredient mixtures with azelaic acids and glycyrrhetic acids as anti-acne agents

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载